Results 281 to 290 of about 218,415 (311)

Hydrocortisone in Severe Community-Acquired Pneumonia.

New England Journal of Medicine, 2023
BACKGROUND Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear.
P. Dequin, F. Meziani, J. Quenot, T. Kamel, J. Ricard, J. Badie, J. Reignier, Nicholas Heming, G. Plantefeve, B. Souweine, G. Voiriot, G. Colin, J. Frat, J. Mira, Nicolas Barbarot, B. François, G. Louis, S. Gibot, C. Guitton, C. Giacardi, S. Hraiech, S. Vimeux, E. L’her, H. Faure, Jean-Etienne Herbrecht, Camille Bouisse, A. Joret, N. Terzi, A. Gacouin, C. Quentin, M. Jourdain, M. Leclerc, Carine Coffre, H. Bourgoin, C. Lengellé, Caroline Caille-Fénérol, B. Giraudeau, A. Le Gouge   +37 more
semanticscholar   +1 more source

Gender differences in Community-acquired Pneumonia.

Minerva Medica, 2020
Community-acquired pneumonia (CAP) is the most common type of lower respiratory tract infection and a major cause of morbidity and mortality in adults worldwide.
Elena Barbagelata, C. Cillóniz, C. Dominedò, A. Torres, A. Nicolini, P. Solidoro   +5 more
semanticscholar   +1 more source

Human genetic and immunological determinants of critical COVID-19 pneumonia

Nature, 2022
Qian Zhang, Paul Bastard, Adrian Gervais
exaly  

Pneumonia

Nature Reviews Disease Primers, 2021
Antonio Torres, Catia Cilloniz, Michael S Niederman   +2 more
exaly